COVID-19
Stéphane Bancel, Moderna’s chief executive officer, stated, “We thank BARDA for this continued commitment to mRNA-1273, our vaccine candidate against COVID-19.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 27, 2020.
It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
An antiviral drug, favipiravir, developed by Glenmark Pharmaceuticals, boosted the time it takes COVID-19 patients with mild to moderate symptoms to improve their health in a Phase III study.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
Francis Collins, the director of the NIH, told STAT they were “really well-powered, rigorously designed clinical trials.”
“Hopefully the approval process will go very quickly, and we think we have a winner here,” Trump told White House reporters on Wednesday.
How long do antibodies against SARS-CoV-2, the novel coronavirus that causes the disease, last? And if they are gone, is your immune system still able to offer protection against getting infected again?
Only days after announcing a COVID-19 vaccine production deal with the UK government, New York-based Pfizer and Germany-based BioNTech signed an even bigger deal with the U.S. government.
PRESS RELEASES